Joshua Sabari, MD

NYU Langone Health

Latest Videos

Expert discussion on managing side effects of EGFR inhibitors in non-small cell lung cancer (NSCLC) with Dr. Azam Farooqi, Dr. Joshua Sabari, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Videos & Podcasts

05/18/2026

How To Manage Side Effects of EGFR Inhibitors in NSCLC

Azam Farooqui, MDJoshua Sabari, MDRahul Gosain, MD, MBARohit Gosain, MD

1. OncUpdates panel featuring leading oncologists discussing advances in EGFR-Mutant NSCLC treatment strategies.

NACLC 2025

12/30/2025

EP. 5: Closing Perspectives on Advancing Care in EGFR-Positive NSCLC

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

Advances in managing toxicities in Mariposa including IRRs, VTEs, and rash with expert strategies by Dr. Joshua Sabari, Dr. Danny Nguyen, Dr. Alexander Spira, and Dr. Edgardo Santos, featured on OncUpdates.

NACLC 2025

12/29/2025

Ep. 4: Managing Toxicities in MARIPOSA: Mitigating Treatment-Related Adverse Events

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

OncUpdates panel discussing clinical insights on escalation versus de-escalation in EGFR-positive NSCLC with doctors Joshua Sabari, Danny Nguyen, Alexander Spira, Edgardo Santos, and Eric Singhi.

NACLC 2025

12/27/2025

Ep. 3: Clinical Insights: Escalation vs De-escalation in EGFR-Positive NSCLC

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

1. Expert panel on CNS activity and resistance discussing Amivantamab and Lazertinib for cancer treatment with Dr. Joshua Sabari, Dr. Edgardo Santos, Dr. Eric Singhi, and Dr. Alexander Spira.

NACLC 2025

12/21/2025

Ep. 2: CNS Control and Resistance: Panel Examines Amivantamab Plus Lazertinib

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

EGFR-Mutant NSCLC survival updates featuring experts Dr. Danny Nguyen, Dr. Eric Singhi, Dr. Alexander Spira, Dr. Edgardo Santos, and Dr. Joshua Sabari discussing Mariposa & FLAURA2 studies.

NACLC 2025

12/19/2025

Ep. 1: Overall Survival Updates in EGFR-Positive NSCLC: MARIPOSA and FLAURA2

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

EGFR+ NSCLC metastatic cancer research researchers Dr. Joshua Sabari Dr. Danny Nguyen Dr. Eric Singhi Dr. Alexander Spira Dr. Edgardo Santos oncology clinical insights oncology updates.

NACLC 2025

12/16/2025

Clinical Insights: Metastatic EGFR+ NSCLC from MARIPOSA and PALOMA-3

Joshua Sabari, MDAlexander Spira, MD, PhD, FACP, FASCODanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MD

FDA approval of Zongertinib in HER2-mutated NSCLC for targeted cancer treatment.

Videos & Podcasts

08/25/2025

FDA Approval of Zongertinib in HER2-Mutated NSCLC

Joshua Sabari, MDRahul Gosain, MD, MBARohit Gosain, MD